Work

Everolimus (EVE) exposure as a predictor of toxicity (Tox) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.4566

Authors: Timothy W. Synold, Melissa Plets, Catherine M. Tangen, Elisabeth I. Heath, Ganesh S. Palapattu, Philip C. Mack, Mark N. Stein, Maxwell V. Meng, Primo Lara, Nicholas J. Vogelzang, Ian Murchie Thompson, Christopher W. Ryan

Institutions: City Of Hope National Medical Center, Fred Hutch Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Michigan, UC Davis Comprehensive Cancer Center, Rutgers Cancer Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Comprehensive Cancer Centers of Nevada, The University of Texas at San Antonio Health Science Center, OHSU Knight Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3038096460

Cites:

Cited by: 2

Related to: 10